Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
McKesson
Julphar
Medtronic
Chubb
Covington
Cantor Fitzgerald
Deloitte
Cerilliant
US Department of Justice

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 9,345,750 protect, and when does it expire?


Patent ► Subscribe protects TOUJEO SOLOSTAR and is included in one NDA.

This patent has fifty-six patent family members in thirty-seven countries.

Summary for Patent: ► Subscribe

Title:Long-acting formulations of insulin
Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.
Inventor(s): Becker; Reinhard (Frankfurt am Main, DE), Hahn; Annke (Frankfurt am Main, DE), Boderke; Peter (Schwalbach, DE), Fuerst; Christiane (Frankfurt am Main, DE), Mueller; Werner (Frankfurt am Main, DE), Werner; Ulrich (Frankfurt am Main, DE)
Assignee: SANOFI (Paris, FR)
Application Number:14/220,562
Patent Claim Types:
see list of patent claims
Formulation; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Us Services
TOUJEO SOLOSTAR
insulin glargine recombinant
SOLUTION;SUBCUTANEOUS206538-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10305532May 19, 2010
10305780Jul 13, 2010
11305140Feb 10, 2011

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20130040824► Subscribe
Japan2015172068► Subscribe
Japan2013147509► Subscribe
Japan5269945► Subscribe
Japan2011241213► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
Farmers Insurance
Medtronic
Citi
Cantor Fitzgerald
Baxter
Cerilliant
Johnson and Johnson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot